Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
New multiple sclerosis phenotypic classification.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
The INCAT disability score: A critical analysis of its measurement properties.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
Santhera to discontinue sale of Catena® in Canada
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Biogen Idec receives negative opinion from the CHMP on Fampyra
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
New approaches in the management of multiple sclerosis.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Patient reported outcome measures in neurogenic bladder.
The interplay between the intestinal microbiota and the brain.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP

Pages